Abstract:Aims: A number of studies have attempted to demonstrate the benefits associated with personalized antiplatelet therapy guided by platelet function testing, which has led to disappointing findings. In this study, we used a new platelet function test to guide antiplatelet therapy in stable coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI). Methods and results In the present randomized controlled trial, a total of 2237 patients with stable CAD undergoing PCI were randomly chosen to be administered personalized antiplatelet therapy (personalized group; n=1123) or standard antiplatelet treatment (standard group; n=1114). The patients in the standard therapy group, without detecting the platelet aggregation rate, were administered a 75mg/day clopidogrel maintenance dosage plus 100mg/day of aspirin for at least 6months after the procedure. For the patients in the personalized therapy group, the antiplatelet strategy was performed according to the maximum aggregation rate (MAR), determined using a novel platelet analyser, PL-12. If MAR>55%, 90mg ticagrelor was administered twice daily plus 100mg/day of aspirin after PCI. If MAR <= 55%, 75mg/day clopidogrel plus 100mg/day of aspirin was administered after PCI. The primary endpoint was net clinical adverse events, which were a composite of cardiac death, myocardial infarction, stroke, stent thrombosis, urgent revascularization, and bleeding [Bleeding Academic Research Consortium (BARC) definitions, Type 2, 3, or 5], in the 180-day period after randomization. The primary endpoint was reached in 58 patients in the personalized group, compared with 85 patients in the standard group [5.1% vs. 7.5%, hazard ratio (HR) 0.678, 95% confidence interval (CI) 0.486-0.947, P=0.023], on intention-to-treat analysis. We also found that the net clinical adverse events (including ischaemic and bleeding events) were significantly reduced in the personalized group at 30days after PCI compared to the standard group (1.5% vs. 3.0%, HR 0.510, 95% CI 0.284-0.915, P=0.020). We did not find a significant difference in major bleeding events at either the 30-day (0.5% vs. 0.3%, P=0.322) or the 180-day follow-up (2.1% vs. 1.6%, P=0.364) between the two groups. Conclusion The present study suggests that personalized antiplatelet therapy according to MAR can significantly improve the net clinical benefit 180-days after PCI.

How to Select Antiplatelet Therapy in Patients with Acute Coronary Syndrome, According to Platelet Function Testing or Pharmacogenomic Testing?

Advances and Perspectives in methods for identifying high platelet reactivity

Optimal-Versus Standard-Antiplatelet Therapy for Patients with High On-Treatment Platelet Reactivity: 2-Year Outcomes of the Multicenter, Randomized Optimal Antiplatelet Therapy (opt) Trial

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate

Latest Evidence in Personalized Antiplatelet Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding

Is platelet function testing at the acute phase under P2Y12 inhibitors helpful in predicting bleeding in real-life patients with acute coronary syndrome? The AVALANCHE study

Clinical pharmacology of antiplatelet drugs

Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes

A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel

Personalised antiplatelet therapies for coronary artery disease: what the future holds

Role of platelet function testing in acute coronary syndromes: a meta-analysis

Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology

Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials

Research Progress of Antiplatelet Treatment Strategy for Patients with Acute Coronary Syndrome

P2Y12-ADP receptor antagonists: Days of future and past

Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing PCI: a randomized controlled clinical trial.

Why Me? To Be an Ultra-Responder to Antiplatelet Therapy: A Case Report

High On-Treatment Platelet Reactivity As Predictor of Long-term Clinical Outcomes in Stroke Patients with Antiplatelet Agents.

Comparison of Unguided De-Escalation Versus Guided Selection of Dual Antiplatelet Therapy After Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis

Current status of secondary prevention medication usage and their relation with on-treatment platelet reactivity